US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Processa Pharmaceuticals, Inc. - Common Stock
(NQ:
PCSA
)
1.610
-0.010 (-0.62%)
Delayed Quote
Updated: 3:56 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Processa Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
January 09, 2026
Via
ACCESS Newswire
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
December 26, 2025
Via
ACCESS Newswire
TOMI Environmental (NASDAQ: TOMZ) | Listeria in Packaged Meals – A Public Health Alert! More Stocks Inside
October 07, 2025
Via
AB Newswire
Topics
Death
Lawsuit
Product Recall
Peraso Inc. (NASDAQ: PRSO) Signals Turnaround – Reports Financials August 11, 2025 – More Stocks Inside
August 07, 2025
Via
AB Newswire
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
August 07, 2025
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 18, 2025
Via
ACCESS Newswire
Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside
June 17, 2025
Via
AB Newswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Phase 2 Clinical Trial Dosing Has Commenced
October 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024
September 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2024 Financial Results, Provides Updates
August 28, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri
August 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
July 30, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Seasoned Veteran as Chief Financial Officer
July 17, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Efficacy Results from Phase 1b Trial
June 11, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference
May 06, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs
April 30, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
April 11, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
March 28, 2024
Via
Investor Brand Network
TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
March 28, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
March 25, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
February 21, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
February 02, 2024
Via
Investor Brand Network
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
January 26, 2024
Via
Investor Brand Network
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
January 26, 2024
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
January 25, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer
January 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split
January 18, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024
January 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial
December 19, 2023
Via
Investor Brand Network
< Previous
1
2
3
Next >
